In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment

Mostrar otras versiones (1)

Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection in vitro, generating interest in its use for the treatment or preventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wotring, Jesse W., McCarty, Sean M., Shafiq, Khadija, Zhang, Charles J., Nguyen, Theophilus, Meyer, Sophia R., Fursmidt, Reid, Mirabelli, Carmen, Clasby, Martin C., Wobus, Christiane E., O’Meara, Matthew J., Sexton, Jonathan Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412300/
https://www.ncbi.nlm.nih.gov/pubmed/36016172
http://dx.doi.org/10.3390/vaccines10081284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412300/
https://www.ncbi.nlm.nih.gov/pubmed/36016172
http://dx.doi.org/10.3390/vaccines10081284

Ejemplares similares